RCP Diagnostics Licenses Its Protein Marker to Biomarker Technologies

RCP Diagnostics™ has announced that they have entered into a licensing agreement with Biomarker Technologies to allow Biomarker to use RCP's protein marker, riboflavin carrier protein, in conjunction with Biomarker's blood diagnostic for breast cancer, called the BT Test™.

Biomarker Technologies launched its second clinical study the week of April 23rd, which will involve 930 women and is expected to take four to six months to complete.

RCP's President, William Gartner said, "Due to the high sensitivity and the early stage differentiation of breast cancer demonstrated by RCP, Biomarker Technologies is investigating the incorporation of this marker into their latest clinical study as a potential contributor to the BT Test's panel of markers."

"We will be evaluating RCP both as an independent marker and as a synergistic component to the BT Test."

Under the terms of the agreement, Biomarker will use the RCP marker only for the diagnosis of breast cancer.

The clinical study is being coordinated through Phoenix-area physicians, clinics and imaging centers.

Among them will be BenOra Imaging, Scottsdale Medical Imaging Ltd, Arizona BreastNet and a private board certified breast cancer surgeon and specialist, Dr. Christa Corn.

In all, approximately 15 to 20 physicians and clinics are expected to participate in the study. Kronos Science Laboratories, a certified CLIA laboratory in Phoenix, will be performing the sample analysis for the study.

Donald Weber, RCP's VP of Licensing, said, "We expect the combined BT/RCP Test to demonstrate an accuracy of greater than 90 percent with both superior sensitivity and specificity."

"As the first blood diagnostic test of its kind, this Test will play a critical role in assisting physicians in the early diagnosis of breast cancer, which is key to timely treatment intervention and improved survival rates from this devastating disease."